Reversal for Apixaban
Andexanet alfa is the recommended specific reversal agent for apixaban-associated major bleeding, with dosing based on the apixaban dose and timing of last intake. 1
Andexanet Alfa Dosing Algorithm
The 2020 ACC Expert Consensus provides clear dosing guidance 1:
Low-Dose Regimen (400 mg bolus + 480 mg infusion)
Administer when:
- Last apixaban dose ≤5 mg taken <8 hours prior, or timing unknown
- Last apixaban dose (any amount) taken ≥8 hours prior
High-Dose Regimen (800 mg bolus + 960 mg infusion)
Administer when:
- Last apixaban dose >5 mg taken <8 hours prior, or timing unknown
- Unknown apixaban dose taken <8 hours prior
Administration details: Bolus given at 30 mg/min, followed by 2-hour infusion (4 mg/min for low dose, 8 mg/min for high dose) 1
Alternative Reversal Options
If andexanet alfa is unavailable, use prothrombin complex concentrate (PCC) or activated PCC (aPCC) 1. The 2018 EHRA guideline recommends PCC 50 U/kg (with additional 25 U/kg if clinically needed) or aPCC 50 U/kg (max 200 U/kg/day) 2.
Recent evidence shows aPCC and 4F-PCC achieve comparable hemostatic outcomes (77% vs 71% hemostasis) with low thromboembolic rates (1.6% vs 4.9%) 3, though these are off-label uses with less robust evidence than andexanet.
Adjunctive Measures
Consider activated charcoal if apixaban ingestion occurred within 2-4 hours 1. Tranexamic acid (1 g IV, repeat every 6 hours if necessary) can be considered as adjuvant therapy, particularly in severe bleeding 2.
Critical Caveats
Drug level assessment: The ANNEXA-4 study excluded patients with DOAC levels <75 ng/mL as clinically insufficient for reversal 1. If feasible without delaying urgent care, assess drug levels before administering andexanet.
Rebound anticoagulation: Significant apixaban concentrations may reappear after andexanet, particularly after the 2-hour infusion ends 2. Continued clinical and laboratory monitoring is essential.
Thrombotic risk: In ANNEXA-4, thrombotic events occurred in 10% of patients at 30 days, none of whom had resumed anticoagulation 4. The ANNEXA-I trial showed 27.8% mortality at 30 days with andexanet 4.
Pharmacokinetic Considerations
Apixaban half-life ranges from 6-17 hours depending on renal function 1. In patients with normal renal function, plasma levels normalize in 12-24 hours; with CrCl 30-50 mL/min, this extends to 36-48 hours 2. For non-life-threatening bleeding, supportive measures with time may suffice.
Practical Implementation
The evidence strongly supports andexanet alfa as first-line for life-threatening bleeding on apixaban 5, 4, 6, 7. Real-world data shows 78.9% achieved excellent/good hemostasis with periprocedural andexanet use 8, and 80% in the ANNEXA-4 study 4. However, UK audit data reveals 87% of institutions still use 4F-PCC off-label, highlighting availability and cost barriers 9.
When reversal is needed urgently and andexanet is unavailable, do not delay treatment—use PCC or aPCC immediately rather than waiting for andexanet procurement 1, 2.